Ardelyx, Inc. (ARDX) FinancialsARDXArdelyx, Inc.

Ardelyx, Inc. (ARDX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is IBSRELA, accounting for 73.0% of total sales, equivalent to $86.24M. Another important revenue stream is XPHOZAH. Understanding this composition is critical for investors evaluating how ARDX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Ardelyx, Inc. maintains a gross margin of 95.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10.28%, while the net margin is -13.83%. These profitability ratios, combined with a Return on Equity (ROE) of -38.61%, provide a clear picture of how effectively ARDX converts its operational activities into shareholder value.

In the context of the broader market, ARDX competes directly with industry leaders such as ANNX and AMPH. With a market capitalization of $983.69M, it holds a significant position in the sector. When comparing efficiency, ARDX's gross margin of 95.24% stands against ANNX's N/A and AMPH's 50.83%. Such benchmarking helps identify whether Ardelyx, Inc. is trading at a premium or discount relative to its financial performance.

Ardelyx has shown fluctuating revenues with Q2 2026 revenue at $120.88 million but has reported net losses consistently, including a net loss of $16.72 million in Q2 2026. Gross margins are strong, around 95.24%, but the company has a negative net margin of -13.83%.